These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 25306215)

  • 21. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential.
    Kim S; Lahmy R; Riha C; Yang C; Jakubison BL; van Niekerk J; Staub C; Wu Y; Gates K; Dong DS; Konieczny SF; Itkin-Ansari P
    Pancreas; 2015 Jul; 44(5):718-27. PubMed ID: 25894862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
    Wasko UN; Jiang J; Dalton TC; Curiel-Garcia A; Edwards AC; Wang Y; Lee B; Orlen M; Tian S; Stalnecker CA; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Muonio K; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs WP; Hibshman PS; Amparo AM; Hennessey C; Rees MG; Ronan MM; Roth JA; Brodbeck J; Tomassoni L; Bakir B; Socci ND; Herring LE; Barker NK; Wang J; Cleary JM; Wolpin BM; Chabot JA; Kluger MD; Manji GA; Tsai KY; Sekulic M; Lagana SM; Califano A; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Lowe SW; Badgley MA; Aguirre AJ; Vonderheide RH; Stanger BZ; Baslan T; Der CJ; Singh M; Olive KP
    Nature; 2024 May; 629(8013):927-936. PubMed ID: 38588697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.
    von Figura G; Fukuda A; Roy N; Liku ME; Morris Iv JP; Kim GE; Russ HA; Firpo MA; Mulvihill SJ; Dawson DW; Ferrer J; Mueller WF; Busch A; Hertel KJ; Hebrok M
    Nat Cell Biol; 2014 Mar; 16(3):255-67. PubMed ID: 24561622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents.
    Grippo PJ; Sandgren EP
    Int J Cancer; 2012 Sep; 131(5):1243-8. PubMed ID: 22024988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis.
    Hsieh CC; Shyr YM; Liao WY; Chen TH; Wang SE; Lu PC; Lin PY; Chen YB; Mao WY; Han HY; Hsiao M; Yang WB; Li WS; Sher YP; Shen CN
    Oncotarget; 2017 Jan; 8(5):7691-7709. PubMed ID: 28032597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.
    Bishehsari F; Zhang L; Barlass U; Preite NZ; Turturro S; Najor MS; Shetuni BB; Zayas JP; Mahdavinia M; Abukhdeir AM; Keshavarzian A
    Int J Cancer; 2018 Oct; 143(8):1994-2007. PubMed ID: 29756386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer.
    Lee HS; Kim E; Lee J; Park SJ; Hwang HK; Park CH; Jo SY; Kang CM; Hong SM; Kang H; Jo JH; Cho IR; Chung MJ; Park JY; Park SW; Song SY; Han JM; Kim S; Bang S
    EBioMedicine; 2021 Mar; 65():103218. PubMed ID: 33639403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
    Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
    Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The advanced glycation end-product N
    Menini S; Iacobini C; de Latouliere L; Manni I; Ionta V; Blasetti Fantauzzi C; Pesce C; Cappello P; Novelli F; Piaggio G; Pugliese G
    J Pathol; 2018 Jun; 245(2):197-208. PubMed ID: 29533466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. U1 Adaptors Suppress the
    Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
    Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
    Blasco MT; Navas C; Martín-Serrano G; Graña-Castro O; Lechuga CG; Martín-Díaz L; Djurec M; Li J; Morales-Cacho L; Esteban-Burgos L; Perales-Patón J; Bousquet-Mur E; Castellano E; Jacob HKC; Cabras L; Musteanu M; Drosten M; Ortega S; Mulero F; Sainz B; Dusetti N; Iovanna J; Sánchez-Bueno F; Hidalgo M; Khiabanian H; Rabadán R; Al-Shahrour F; Guerra C; Barbacid M
    Cancer Cell; 2019 Apr; 35(4):573-587.e6. PubMed ID: 30975481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.
    Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F
    Gastroenterology; 2013 May; 144(5):1098-106. PubMed ID: 23333712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
    Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM
    Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.